1700632961
1700632962
[40] Overgaard K, Hansen MA, Jensen SB, et al. Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: A dose-response study. BMJ. 1992, 305
:556-561.
1700632963
1700632964
[41] Chesnut CH III，Silverman S, Andriano K, et al. for the PROOF study Group. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: The prevent recurrence of osteoporotic fractures study. Am J Med, 2000, 109
:267-276.
1700632965
1700632966
[42] Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Solomon Epstein Clinical Therapeutics, 2006, 28
:151-173.
1700632967
1700632968
[43] Selye H. On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology, 1932, 16
:547-558.
1700632969
1700632970
[44] Silverberg SJ, Shane E, de la Cruz L, et al. Skeletal disease in primary hyperparathyroidism. J Bone Miner Res, 1989, 4
:283-291.
1700632971
1700632972
[45] Rubin MR, Cosman F, Lindsay R, et al. The anabolic effects of parathyroid hormone. Osteoporos Int, 2002, 13
:267-277.
1700632973
1700632974
[46] Juppner H, Abou-Samra AB, Freeman M, et al. A G protein-linked receptor for parathyroid hormone and parathyroid hormone-related peptide. Science, 1991, 254
:1024-1026.
1700632975
1700632976
[47] Canalis E, Centrella M, Burch W, et al. Insulin-like growth factor Ⅰ mediates selective anabolic effects of parathyroid hormone in bone cultures. J Clin Invest, 1989, 83
:60-65.
1700632977
1700632978
[48] Hock JM. Anabolic PTH targets proliferating cells of the primary spongiosa in young rats and increases the number differentiating into osteoblasts. J Bone Miner Res, 1994, 9
:5421.
1700632979
1700632980
[49] Dobnig H, Turner RT. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology, 1995, 136
:3632-3638.
1700632981
1700632982
[50] Jilka RL, Weinstein RS, Bellido T, et al. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest, 1999, 104
:439-446.
1700632983
1700632984
[51] Bellido T, Ali AA, Plotkin LI, et al. Proteasomal degradation of Runx 2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism. J Biol Chem, 2003, 278
:50259-50272.
1700632985
1700632986
[52] Locklin RM, Khosla S, Turner RT, et al. Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone. J Cell Biochem, 2003, 89
:180-190.
1700632987
1700632988
[53] Hofbauer LC, Heufelder AE. The role of receptor activator of nuclear factor-kappa B ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. J Clin Endocrinol Metab, 2000, 85
:2355-2363.
1700632989
1700632990
[54] Ma YL, Cain RL, Halladay DL, et al. Catabolic effects of continuous human PTH [1-38] in vivo is associated with sustained stimulation of RANKL and inhibition of osteoprotegerin and gene-associated bone formation. Endocrinology, 2001, 142
:4047-4054.
1700632991
1700632992
[55] Lindsay R, Nieves J, Formica C, et al. Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis. Lancet, 1997, 350
:550-555.
1700632993
1700632994
[56] Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone [1-34] on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med, 2001, 344
:1434-1441.
1700632995
1700632996
[57] Hodsman AB, Fraher LJ, Ostbye T, et al. An evaluation of several biochemical markers for bone formation and resorption in a protocol utilizing cyclical parathyroid hormone and calcitonin therapy for osteoporosis. J Clin Invest, 1993, 91
:1138-1148.
1700632997
1700632998
[58] McClung MR, San Martin J, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med, 2005, 165
:1762-1768.
1700632999
1700633000
[59] Yonemura K, Kimura M, Miyaji T, et al. Short-term effects of vitamin K administration on prednisone-induced loss of bone mineral density in patients with chronic glomerulonephritis. Calcif Tissue Int, 2000, 66
:123-128.
1700633001
1700633002
[60] 廖二元，超楚生．内分泌学．第二版，北京：人民卫生出版社，2004，1816-1817.
1700633003
1700633004
[61] Maalouf N, Wehbe J, Nehme A, et al. Osteoporosis: combination therapy for better or worse. J Musculoskel Neuron Interact, 2003, 3
:141-147.
1700633005
1700633006
[62] Simon JA, Mack CJ. Treatment of osteoporosis: combination therapies. Int J Fertil, 2003, 48
:127-131.
1700633007
1700633008
[63] Compston JE, Watts NB. Combination therapy for postmenopausal osteoporosis. Clin Endocrinol, 2002, 56
:565-569.
1700633009
1700633010
[64] Ettinger B, Bilezikian JP. Editorial: For osteoporosis, are two antiresorptive drugs better than one. J Clin Endocrinol Metab, 2002, 87
:983-984.
[
上一页 ]
[ :1.700632961e+09 ]
[
下一页 ]